Groups | Placebo | GCE | EGML | |||
---|---|---|---|---|---|---|
 | Before | After | Before | After | Before | After |
HTR (%) | 21.36 ± 1.56 | 22.49 ± 1.94 | 21.08 ± 1.48 | 23.14 ± 1.38 | 20.43 ± 1.17 | 23.77* ± 1.16 |
AI | 4.51 ± 0.58 | 4.31 ± 0.49 | 4.68 ± 0.33 | 3.82 ± 0.31 | 4.14 ± 0.35 | 3.43 ± 0.21 |
FFA (mmol/L) | 0.54 ± 0.04 | 0.50 ± 0.03 | 0.49 ± 0.03 | 0.41 ± 0.03 | 0.49 ± 0.03 | 0.40* ± 0.02 |
PL (mmol/L) | 1.58 ± 0.05 | 1.53 ± 0.05 | 1.61 ± 0.05 | 1.56 ± 0.05 | 1.64 ± 0.06 | 1.56 ± 0.04 |
Apo A-1 ( μg/dL) | 1.82 ± 0.10 | 1.56 ± 0.04 | 1.72 ± 0.08 | 1.85 ± 0.12 | 1.66 ± 0.03 | 1.88 ± 0.15 |
Apo B ( μg/dL) | 4.11 ± 0.33 | 4.10 ± 0.34 | 6.27 ± 0.63 | 5.55 ± 0.50 | 5.17 ± 0.40 | 4.70 ± 0.37 |
Apo B/Apo A-1 | 2.26 ± 0.63 | 2.62 ± 0.63 | 3.65 ± 0.42 | 3.00 ± 0.29 | 3.11 ± 0.23 | 2.50* ± 0.26 |